top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


What a Trip to the Salon Reminded Me About Biotech, Healthcare, and Life
Before heading to Biotech Week, an unexpected salon visit reminded me that behind every breakthrough in biotech and healthcare are real people—and lives science has the potential to improve.
sharonshieldsconsu
12 hours ago4 min read


Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure
Q3 2026 medtech results showed a widening gap between fast-growing innovators and companies facing pressure in key product lines. Abbott led among larger players, while Profound Medical and IRadimed posted strong growth from smaller bases. MiMedx and Dentsply Sirona struggled with revenue declines, highlighting how product mix and demand can shape performance across the sector.
sharonshieldsconsu
Nov 123 min read


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read
bottom of page